Mirum Pharmaceuticals appointed Rob Myers, M.D., to replace Joanne Quan, M.D., as chief medical officer, while approving Quan’s 2026 annual target Bonus at the 100% achievement level. Investors must track the September Leadership handover and expected separation terms, including severance eligibility and changes to vested stock-option exercise rights.

Key Highlights

  • Rob Myers is expected to begin employment on September 21, while Joanne Quan’s employment is expected to end on October 19.
  • Mirum expects to provide the completed separation agreement with a later quarterly or annual report, subject to its effective date.
  • Rob Myers, M.D. Is expected to become Mirum Pharmaceuticals’ chief medical officer after beginning employment on September 21.

Quan’s 2026 annual target bonus was approved at the 100% achievement level, subject to conditions in the final separation agreement. Myers is expected to start on September 21. Quan stopped serving as chief medical officer on September 2, and her employment is expected to end on October 19.

Separation Terms Include Bonus and Option Changes

Mirum (NASDAQ: MIRM) expects to enter into a separation agreement with Quan in connection with her departure. Mirum expects to include the completed agreement with its Quarterly Report covering the three months ending September 30 or its Annual Report for the year ending December 31, subject to the agreement’s effective date.